Alison Wolfreys

Slough, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Review of the Technical, Toxicological, and PKPD Considerations for Conducting Inhalation Toxicity Studies on Biologic Pharmaceuticals-The Outcome of a Cross-Industry Working Group Survey.

Review of the Technical, Toxicological, and PKPD Considerations for Conducting Inhalation Toxicity Studies on Biologic Pharmaceuticals-The Outcome of a Cross-Industry Working Group Survey.

Journal: Toxicologic pathology

Published: February 03, 2021

BSTP Review of 12 Case Studies Discussing the Challenges, Pathology, Immunogenicity, and Mechanisms of Inhaled Biologics.

BSTP Review of 12 Case Studies Discussing the Challenges, Pathology, Immunogenicity, and Mechanisms of Inhaled Biologics.

Journal: Toxicologic pathology

Published: January 18, 2021

Sclerostin Downregulation Globally by Naturally Occurring Genetic Variants, or Locally in Atherosclerotic Plaques, Does Not Associate With Cardiovascular Events in Humans.

Sclerostin Downregulation Globally by Naturally Occurring Genetic Variants, or Locally in Atherosclerotic Plaques, Does Not Associate With Cardiovascular Events in Humans.

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Published: December 02, 2020

Justification for species selection for pharmaceutical toxicity studies.

Justification for species selection for pharmaceutical toxicity studies.

Journal: Toxicology research

Published: August 17, 2020

Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture.

Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture.

Journal: Regulatory toxicology and pharmacology : RTP

Published: February 18, 2020

The use of emerging safety biomarkers in nonclinical and clinical safety assessment - The current and future state: An IQ DruSafe industry survey.

The use of emerging safety biomarkers in nonclinical and clinical safety assessment - The current and future state: An IQ DruSafe industry survey.

Journal: Regulatory toxicology and pharmacology : RTP

Published: February 17, 2020

Opportunities for use of one species for longer-term toxicology testing during drug development: A cross-industry evaluation.

Opportunities for use of one species for longer-term toxicology testing during drug development: A cross-industry evaluation.

Journal: Regulatory toxicology and pharmacology : RTP

Published: October 09, 2019

Identification of a Novel Allosteric Inhibitory Site on Tryptophan Hydroxylase 1 Enabling Unprecedented Selectivity Over all Related Hydroxylases.

Identification of a Novel Allosteric Inhibitory Site on Tryptophan Hydroxylase 1 Enabling Unprecedented Selectivity Over all Related Hydroxylases.

Journal: Frontiers in pharmacology

Published: March 08, 2017

Optimized nonclinical safety assessment strategies supporting clinical development of therapeutic monoclonal antibodies targeting inflammatory diseases.

Optimized nonclinical safety assessment strategies supporting clinical development of therapeutic monoclonal antibodies targeting inflammatory diseases.

Journal: Drug development research

Published: February 22, 2014

Challenges for inhaled drug discovery and development: Induced alveolar macrophage responses.

Challenges for inhaled drug discovery and development: Induced alveolar macrophage responses.

Journal: Advanced drug delivery reviews

Published: November 01, 2013

Showing 1-10 of 10

Last Updated: 09/26/2026